TFEB-NF-κB inflammatory signaling axis: a novel therapeutic pathway of Dihydrotanshinone I in doxorubicin-induced cardiotoxicity | Journal of Experimental & Clinical Cancer Research | Full Text

TFEB-NF-κB inflammatory signaling axis: a novel therapeutic pathway of Dihydrotanshinone I in doxorubicin-induced cardiotoxicity | Journal of Experimental & Clinical Cancer Research | Full Text

TFEB-NF-κB inflammatory signaling axis: a novel therapeutic pathway of Dihydrotanshinone I in doxorubicin-induced cardiotoxicity

Doxorubicin is effective in a variety of solid and hematological malignancies. Unfortunately, clinical application of doxorubicin is limited due to a cumulative dose-dependent cardiotoxicity. Dihydrotanshinone...

Authors:Xiaoping Wang, Qiyan Wang, Weili Li, Qian Zhang, Yanyan Jiang, Dongqing Guo, Xiaoqian Sun, Wenji Lu, Chun Li and Yong Wang

Citation:Journal of Experimental & Clinical Cancer Research 2020 39:93

Content type:Research

Published on: 24 May 2020

• ViewFull Text
 
• ViewPDF